Akston has used its Ambifect™ Fc-fusion protein platform to develop a diverse pipeline of therapeutic candidates for indications in both human and animal health.

Akston has licensing agreements with partners and maintains close involvement in the development process.

Human Health

candidate
indication
mechanism
partner
Discovery
Pre-Clinical
Phase I
Phase II
Phase III
Market
AKS-452
COVID-19 Vaccine
Induce and/or augment antibody titers
Indication: COVID-19 Vaccine
Market

AKS-452 is a CoV-2 protein subunit vaccine based on the Ambifect™ Fc-fusion protein platform. Akston and Strides Group have signed a licensing, manufacturing, and commercialization agreement to launch AKS-452 worldwide as AmbiVax-C™.

Patent Info
AKS-107
Human T1D Intervention
Interrupt insulin autoimmunity
Indication: Human T1D Intervention
Pre-Clinical

Akston has developed AKS-107, a designer Fc-insulin fusion protein, to interrupt the process leading to insulin autoimmunity. Akston has partnered with the Helmsley Charitable Trust and the National Institutes of Health (NIH).

Patent Info
AKS-440
Human Weekly Insulin
FcRn recycled insulin for
once-a-week dosing
Indication: Human Weekly Insulin
Pre-Clinical

Akston has developed AKS-440, a novel human insulin candidate based on the Ambifect™ Fc-fusion protein platform, intended to be a once-a-week injectable diabetes therapy. It is currently in pre-clinical development.

Patent Info
AKS-130
Oncology
Disrupt insulin receptor signaling in cancer cells
Indication: Oncology
Pre-Clinical

Akston has developed AKS-130, an insulin-Fc fusion protein designed to lower blood glucose levels in order to target the tumor cell insulin receptors. It is currently in pre-clinical development.

Patent Info

Animal Health

candidate
indication
mechanism
partner
Discovery
Pre-Clinical
Clinical
Market
AKS-321d
Canine Diabetes
FcRn recycled insulin for
once-a-week dosing
Indication: Canine Diabetes
Clinical

Akston has developed AKS-321d, a once-a-week insulin therapies for dogs intended to replace the current twice-a-day veterinary insulin treatments. Akston has partnered with Dechra Pharmaceuticals PLC to commercialize AKS-321d.

Patent Info
AKS-425c
Feline Diabetes
FcRn recycled insulin for
once-a-week dosing
Indication: Feline Diabetes
Clinical

Akston has developed AKS-425c, a once-a-week insulin therapies for cats intended to replace the current twice-a-day veterinary insulin treatments. Akston has partnered with Dechra Pharmaceuticals PLC to commercialize AKS-425c.

Patent Info

Platform

Ambifect™ platform for all candidates

Process

Discovery to therapeutics to patients